FOLH1 and neoplasm: Continuing from the previous trial and extending the treatment observation period to 58 days, the TGI reached 98% for 177Lu-PSMA-NARI-56 and 58% for 177Lu-PSMA-617, both of which showed an increase in tumor inhibition, although there was a greater difference in the size of the tumors in the mice treated with 177Lu-PSMA-617.